Trial Profile

A Phase 2 Dose Optimization Trial Evaluating a CD46-Targeted Antibody-Drug Conjugate (FG-3246) in Patients With Metastatic Castration-Resistant Prostate Cancer

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 15 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs FG 3246 (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Sponsors FibroGen

Most Recent Events

12 May 2025 According to a FibroGen media release, company to anticipate initiation of Phase 2 monotherapy dose optimization study of FG-3246 in mCRPC in the third quarter of 2025.
02 Apr 2025 Planned initiation date changed from 1 Mar 2025 to 30 Apr 2025.
28 Mar 2025 According to a FibroGen media release, company anticipate topline results from the Phase 2 portion of the study anticipated in 2H 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com